NA Hereditary Cancer Testing Market - Industry Trends and Forecast to 2029
North America hereditary cancer testing market is projected to register a CAGR of 13.3% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.
Market Segmentation
North America Hereditary Cancer Testing Market, By Test Type (Multi Panel Set, and Single-Site Genetic Test) Diagnosis Type (Biopsy, Imaging, Lab Tests) Technology (Sequencing, Polymerase Chain Reaction (PCR), Microarray) Disease Type (Hereditary Breast & Ovarian Cancer Syndrome, Cowden Syndrome, Lynch Syndrome, Hereditary Leukemia And Hematologic Malignancies Syndromes, Familial Adenomatous Polyposis (FAP), Li-Fraumeni Syndrome, Vol-Hippel Lindau Disease, Multiple Endocrine Neoplasias (MEN) Syndromes) End User (Hospitals, Clinics, Laboratories, Radiology Centers, Diagnostic Centers, Others) Distribution Channel (Direct Tender, Retail Sales) Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029
Some of the factors boosting the growth of the hereditary cancer testing market are:
• Rising incidence of hereditary cancer
• Increased demand for non-invasive testing methods
Market Players
The key market players for North America hereditary cancer testing market are listed below:
• Invitae Corporation
• Illumina, Inc.
• Natera, Inc.
• CENTOGENE N.V.
• 4baseCare
• Biocartis
• Fulgent Genetics
• Ambry Genetics
• BioReference
• PerkinElmer Inc.
• LifeLabs
• Abbott
• BIO-HELIX
• Cepheid
• Eurofins Scientific
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook